Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:HUMANASDAQ:IVVDNASDAQ:RZLTNASDAQ:UPXI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHUMAHumacyte$2.36+1.3%$1.98$1.15▼$9.79$366.08M23.85 million shs2.04 million shsIVVDInvivyd$0.75+3.1%$0.73$0.35▼$2.74$89.85M0.634.54 million shs522,900 shsRZLTRezolute$4.07-1.5%$3.79$2.22▼$6.19$348.06M1.04577,755 shs472,352 shsUPXIUpexi$10.79+12.5%$9.96$1.90▼$22.57$409.11M-0.3884,136 shs501,631 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHUMAHumacyte0.00%-2.07%-5.22%-28.92%-60.24%IVVDInvivyd0.00%-11.55%-7.44%+1.49%-46.50%RZLTRezolute0.00%-7.50%+3.04%+33.44%+4.90%UPXIUpexi0.00%-14.30%+9.21%+363.09%+34.84%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationHUMAHumacyte2.365 of 5 stars3.51.00.00.02.52.50.6IVVDInvivyd2.8481 of 5 stars3.64.00.00.00.03.30.6RZLTRezolute2.5928 of 5 stars3.61.00.00.02.74.20.0UPXIUpexi2.844 of 5 stars3.53.00.00.02.63.30.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceHUMAHumacyte 3.00Buy$11.71396.37% UpsideIVVDInvivyd 3.25Buy$5.85681.04% UpsideRZLTRezolute 3.14Buy$11.83190.75% UpsideUPXIUpexi 3.00Buy$16.0048.29% UpsideCurrent Analyst Ratings BreakdownLatest IVVD, HUMA, UPXI, and RZLT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/16/2025UPXIUpexiCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Overweight$16.006/9/2025HUMAHumacyteD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.005/28/2025IVVDInvivydHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$10.00 ➝ $5.005/16/2025IVVDInvivydD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.005/14/2025HUMAHumacyteHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$4.005/14/2025HUMAHumacyteBenchmarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$17.00 ➝ $14.005/14/2025RZLTRezoluteWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$12.005/13/2025HUMAHumacyteD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.00 ➝ $25.004/28/2025RZLTRezoluteHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.00 ➝ $14.003/26/2025HUMAHumacyteD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.00 ➝ $25.003/26/2025IVVDInvivydHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00(Data available from 6/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookHUMAHumacyte$517K708.09N/AN/A($0.41) per share-5.76IVVDInvivyd$25.38M3.54N/AN/A$0.56 per share1.34RZLTRezoluteN/AN/AN/AN/A$2.19 per shareN/AUPXIUpexi$26M15.74N/AN/A$6.24 per share1.73Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateHUMAHumacyte-$148.70M-$0.69N/AN/AN/AN/AN/A-73.59%8/12/2025 (Estimated)IVVDInvivyd-$169.93M-$1.20N/A6.81N/A-389.01%-165.24%-99.71%8/13/2025 (Estimated)RZLTRezolute-$68.46M-$1.15N/AN/AN/AN/A-70.09%-63.08%N/AUPXIUpexi-$23.66MN/A0.00∞N/A-135.86%-535.19%-122.94%7/8/2025 (Estimated)Latest IVVD, HUMA, UPXI, and RZLT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/16/2025Q1 2025UPXIUpexiN/A-$2.87N/A-$2.87N/A$3.16 million5/15/2025Q1 2025IVVDInvivyd-$0.04-$0.14-$0.10-$0.14$34.45 million$11.30 million5/13/2025Q1 2025HUMAHumacyte-$0.19-$0.10+$0.09$0.28$0.46 million$0.52 million5/13/2025Q3 2025RZLTRezolute-$0.22-$0.27-$0.05-$0.27N/AN/A3/28/2025Q4 2024HUMAHumacyte-$0.23-$0.16+$0.07-$0.16$0.64 million$7.23 million3/20/2025Q4 2024IVVDInvivyd-$0.25-$0.15+$0.10-$0.15$13.57 million$13.80 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthHUMAHumacyteN/AN/AN/AN/AN/AIVVDInvivydN/AN/AN/AN/AN/ARZLTRezoluteN/AN/AN/AN/AN/AUPXIUpexiN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioHUMAHumacyte0.363.683.28IVVDInvivydN/A1.531.53RZLTRezoluteN/A8.438.43UPXIUpexi0.310.370.24Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipHUMAHumacyte44.71%IVVDInvivyd70.36%RZLTRezolute82.97%UPXIUpexi5.68%Insider OwnershipCompanyInsider OwnershipHUMAHumacyte5.10%IVVDInvivyd25.40%RZLTRezolute18.39%UPXIUpexi31.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableHUMAHumacyte150155.12 million147.21 millionOptionableIVVDInvivyd100119.96 million89.49 millionOptionableRZLTRezolute4085.52 million69.79 millionOptionableUPXIUpexi13037.92 million25.93 millionOptionableIVVD, HUMA, UPXI, and RZLT HeadlinesRecent News About These CompaniesCantor Fitzgerald Upgrades Upexi (NASDAQ:UPXI) to OverweightJune 18 at 1:23 AM | americanbankingnews.comSOL Drops Below $150 After Sell-Off Despite Growing Institutional Adoption NarrativeJune 17 at 1:31 PM | coindesk.comUpexi, Inc. CSO Brian Rudick to Speak at ICR Conference on Public Market Crypto StrategiesJune 17 at 9:29 AM | quiverquant.comUpexi's Chief Strategy Officer to Present at The ICR Conference Spotlight Series on June 20thJune 17 at 9:00 AM | globenewswire.comUpexi, Inc. (NASDAQ:UPXI) Sees Large Growth in Short InterestJune 17 at 3:57 AM | marketbeat.comCantor Fitzgerald Upgrades Upexi (NASDAQ:UPXI) to "Overweight"June 16, 2025 | marketbeat.comUpexi CEO and CSO to Host Fireside Chat on Thursday, June 26th at 11:00 a.m. ETJune 14, 2025 | seekingalpha.comUpexi (NASDAQ:UPXI) Shares Gap Up - Time to Buy?June 11, 2025 | marketbeat.comUpexi, Inc. Joins Webull Corporate Connect Service to Enhance Investor Engagement and CommunicationJune 11, 2025 | nasdaq.comHODL On Tight: The Meteoric Rise of Crypto Treasury Companies – Downloadable ReportJune 10, 2025 | finance.yahoo.comHODL On Tight: The Meteoric Rise of Crypto Treasury Companies – Downloadable ReportJune 10, 2025 | finance.yahoo.comUpexi Joins Webull Corporate Connect Service PlatformJune 9, 2025 | globenewswire.comUpexi options begin trading on Nasdaq marketJune 6, 2025 | investing.comUpexi Approved for Options Trading on NasdaqJune 5, 2025 | globenewswire.comWall Street Zen Upgrades Upexi (NASDAQ:UPXI) to HoldJune 2, 2025 | marketbeat.comUpexi, Inc. (NASDAQ:UPXI) Short Interest UpdateMay 31, 2025 | marketbeat.comUpexi to Present at the iAccess Alpha Virtual Best Ideas Summer Investment Conference on June 24-25May 30, 2025 | globenewswire.comUpexi releases presentation detailing Solana treasury strategyMay 29, 2025 | finance.yahoo.comUpexi Partners with Crypto-Native Marketing and Design Firm, GMI Digital, to Drive Solana-Focused StrategyMay 29, 2025 | globenewswire.comUpexi, Inc. Acquires 77,879 Locked SOL for $11.8 Million, Increasing Holdings to 679,677 SOLMay 28, 2025 | quiverquant.comUpexi, Inc. Buys Additional Locked SOL at a Discount for $11.8 millionMay 28, 2025 | taiwannews.com.twNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIVVD, HUMA, UPXI, and RZLT Company DescriptionsHumacyte NASDAQ:HUMA$2.36 +0.03 (+1.29%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$2.38 +0.02 (+0.85%) As of 06/18/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.Invivyd NASDAQ:IVVD$0.75 +0.02 (+3.05%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$0.74 -0.01 (-1.20%) As of 06/18/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Invivyd, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19. The company also has discovery stage candidates for the prevention of seasonal influenza and COVID-19. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.Rezolute NASDAQ:RZLT$4.07 -0.06 (-1.45%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$4.07 0.00 (0.00%) As of 06/18/2025 07:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.Upexi NASDAQ:UPXI$10.79 +1.20 (+12.51%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$10.70 -0.08 (-0.79%) As of 06/18/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Upexi, Inc. manufactures and sells various branded products in the health, wellness, pet, beauty, and other markets. The company was formerly known as Grove, Inc. and changed its name to Upexi, Inc. in August 2022. The company was incorporated in 2018 and is headquartered in Clearwater, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Robinhood Director Sells Millions, But HOOD Stock Eyes Gains Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill Chime’s Smart IPO: Half the Valuation, Double the Strength 3 Tech Stocks With High and Rising Institutional Interest Salesforce Raises Prices: 3 Reasons Its Stock Price Will Follow Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
